RU2000129672A - Quinoline derivatives - Google Patents
Quinoline derivativesInfo
- Publication number
- RU2000129672A RU2000129672A RU2000129672/04A RU2000129672A RU2000129672A RU 2000129672 A RU2000129672 A RU 2000129672A RU 2000129672/04 A RU2000129672/04 A RU 2000129672/04A RU 2000129672 A RU2000129672 A RU 2000129672A RU 2000129672 A RU2000129672 A RU 2000129672A
- Authority
- RU
- Russia
- Prior art keywords
- ethyl
- methyl
- compound
- paragraphs
- treating mammals
- Prior art date
Links
- 229940093918 Quinoline gynecological antiinfectives Drugs 0.000 title 1
- 229940027991 antiseptics and disinfectants Quinoline derivatives Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 241000124008 Mammalia Species 0.000 claims 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 6
- 150000001767 cationic compounds Chemical class 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- -1 methylenedioxy group Chemical group 0.000 claims 4
- 150000002892 organic cations Chemical class 0.000 claims 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 4
- 229910052708 sodium Inorganic materials 0.000 claims 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- RJSYPKWVIJGNLO-UHFFFAOYSA-N CCOClOC Chemical compound CCOClOC RJSYPKWVIJGNLO-UHFFFAOYSA-N 0.000 claims 2
- 229960002887 Deanol Drugs 0.000 claims 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 229940043237 diethanolamine Drugs 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 229910001411 inorganic cation Inorganic materials 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 229940113083 morpholine Drugs 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 2
- MZLKHPDPHGHSOY-UHFFFAOYSA-N (2,3-dioxoindole-1-carbonyl) 2,3-dioxoindole-1-carboxylate Chemical compound O=C1C(=O)C2=CC=CC=C2N1C(=O)OC(=O)N1C2=CC=CC=C2C(=O)C1=O MZLKHPDPHGHSOY-UHFFFAOYSA-N 0.000 claims 1
- NHDURIXSKYSQOE-UHFFFAOYSA-N 5-bromo-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide Chemical compound OC=1C2=C(Br)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 NHDURIXSKYSQOE-UHFFFAOYSA-N 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N Laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 1
- UCFFGYASXIPWPD-UHFFFAOYSA-N Methyl hypochlorite Chemical compound COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 claims 1
- DIKSYHCCYVYKRO-UHFFFAOYSA-N N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide Chemical compound OC=1C2=C(CC)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 DIKSYHCCYVYKRO-UHFFFAOYSA-N 0.000 claims 1
- NNDZSFODGTZLGR-UHFFFAOYSA-N N-ethyl-4-hydroxy-1,5-dimethyl-2-oxo-N-phenylquinoline-3-carboxamide Chemical compound OC=1C2=C(C)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 NNDZSFODGTZLGR-UHFFFAOYSA-N 0.000 claims 1
- DVCXLZGKWGUOIH-UHFFFAOYSA-N N-ethyl-4-hydroxy-5-methoxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide Chemical compound OC=1C2=C(OC)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 DVCXLZGKWGUOIH-UHFFFAOYSA-N 0.000 claims 1
- UODJYZJOKPIRKX-UHFFFAOYSA-N N-ethyl-9-hydroxy-6-methyl-7-oxo-N-phenyl-[1,3]dioxolo[4,5-f]quinoline-8-carboxamide Chemical compound OC=1C2=C3OCOC3=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 UODJYZJOKPIRKX-UHFFFAOYSA-N 0.000 claims 1
- 206010038683 Respiratory disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 150000001718 carbodiimides Chemical class 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 239000008096 xylene Substances 0.000 claims 1
Claims (1)
где R выбран из этила, н-пропила, изопропила, н-бутила, изобутила, втор. -бутила и аллила;
R4 выбран из водорода и фармацевтически приемлемых неорганических или органических катионов;
R5 выбран из метила, этила, н-пропила, изопропила, метокси, этокси, хлора, брома, СF3, и OCHxFy;
где х = 0-2,
у = 1-3, при условии, что
х+у= 3;
R6 представляет собой водород; или
R5 и R6, взятые вместе, образуют метилендиокси группу;
и их любой таутомер.1. New compounds of General formula (I)
where R is selected from ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec. -butyl and allyl;
R 4 is selected from hydrogen and pharmaceutically acceptable inorganic or organic cations;
R 5 is selected from methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, chlorine, bromine, CF 3 , and OCH x F y ;
where x = 0-2,
y = 1-3, provided that
x + y = 3;
R 6 represents hydrogen; or
R 5 and R 6 taken together form a methylenedioxy group;
and any tautomer of them.
предпочтительно метилового или этилового эфира, с анилином формулы (III) в подходящем растворителе, таком как толуол, ксилол и тому подобное; или (В) взаимодействии изатинового ангидрида формулы (IV), с алкиловым эфиром N-алкил-N-фенилкарбамоилуксусной кислоты формулы (V)
предпочтительно метиловым или этиловым эфиром, с использованием сильного основания, например, гидроксида натрия, в подходящем растворителе, таком как N, N-диметилацетамид; или (С) взаимодействии хинолинкарбоновой кислоты формулы (VI) с анилином формулы (III)
с использованием подходящего конденсирующего реагента, предпочтительно карбодиимида или тионилхлорида в присутствии триэтиламина и подходящего растворителя, такого как дихлорметан.16. A method of obtaining a compound of General formula (I), which consists in (A) reacting a complex ester derivative of a quinoline carboxylic acid of formula (II)
preferably methyl or ethyl ether, with the aniline of formula (III) in a suitable solvent such as toluene, xylene and the like; or (B) reacting isatinic anhydride of formula (IV) with an N-alkyl-N-phenylcarbamoylacetic acid alkyl ester of formula (V)
preferably methyl or ethyl ether, using a strong base, for example sodium hydroxide, in a suitable solvent such as N, N-dimethylacetamide; or (C) reacting a quinoline carboxylic acid of formula (VI) with aniline of formula (III)
using a suitable condensing reagent, preferably carbodiimide or thionyl chloride in the presence of triethylamine and a suitable solvent, such as dichloromethane.
где R выбран из этила, н-пропила, изопропила, н-бутила, изобутила, втор. -бутила и аллила;
R4 выбран из водорода и фармацевтически приемлемых неорганических или органических катионов;
R5 выбран из метила, этила, н-пропила, изопропила, метокси, этокси, хлора, брома, СF3, и OCHxFy;
где х= 0-2,
у= 1-3, при условии, что х+у= 3;
R6 представляет собой водород; или
R5 и R6, взятые вместе образуют метилендиокси группу,
и его любого таутомера.17. A method for treating mammals suffering from diseases resulting from an autoimmune reaction and pathological inflammation, comprising administering to said mammal, a compound having the formula (I)
where R is selected from ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec. -butyl and allyl;
R 4 is selected from hydrogen and pharmaceutically acceptable inorganic or organic cations;
R 5 is selected from methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, chlorine, bromine, CF 3 , and OCH x F y ;
where x = 0-2,
y = 1-3, provided that x + y = 3;
R 6 represents hydrogen; or
R 5 and R 6 taken together form a methylenedioxy group,
and its any tautomer.
27. Способ по любому из пп. 16-21, представляющий собой способ лечения млекопитающих, страдающих от воспалительного заболевания кишечника (IBD).26. The method according to any one of paragraphs. 16-21, which is a method of treating mammals suffering from rheumatoid arthritis (RA)
27. The method according to any one of paragraphs. 16-21, which is a method of treating mammals suffering from inflammatory bowel disease (IBD).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9801474A SE9801474D0 (en) | 1998-04-27 | 1998-04-27 | Quinoline Derivatives |
SE9801474-9 | 1998-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000129672A true RU2000129672A (en) | 2003-01-20 |
RU2197481C2 RU2197481C2 (en) | 2003-01-27 |
Family
ID=20411103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000129672/04A RU2197481C2 (en) | 1998-04-27 | 1999-04-26 | Quinoline derivatives |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1073639B1 (en) |
JP (1) | JP4045069B2 (en) |
KR (1) | KR100571534B1 (en) |
CN (1) | CN1113057C (en) |
AP (1) | AP1293A (en) |
AT (1) | ATE228505T1 (en) |
AU (1) | AU747550B2 (en) |
BR (1) | BR9909925B1 (en) |
CA (1) | CA2329788C (en) |
CZ (1) | CZ297439B6 (en) |
DE (1) | DE69904162T2 (en) |
DK (1) | DK1073639T3 (en) |
EE (1) | EE04275B1 (en) |
ES (1) | ES2188242T3 (en) |
HK (1) | HK1036618A1 (en) |
HR (1) | HRP20000726B1 (en) |
HU (1) | HU227709B1 (en) |
ID (1) | ID26277A (en) |
IL (2) | IL138160A0 (en) |
IS (1) | IS2082B (en) |
ME (1) | ME00870B (en) |
NO (1) | NO315606B1 (en) |
NZ (1) | NZ506641A (en) |
OA (1) | OA11547A (en) |
PL (1) | PL190441B1 (en) |
PT (1) | PT1073639E (en) |
RS (1) | RS50029B (en) |
RU (1) | RU2197481C2 (en) |
SE (1) | SE9801474D0 (en) |
TR (1) | TR200003061T2 (en) |
UA (1) | UA60354C2 (en) |
WO (1) | WO1999055678A1 (en) |
ZA (1) | ZA200004601B (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0002320D0 (en) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
SE0201778D0 (en) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
KR100908655B1 (en) | 2002-11-27 | 2009-07-21 | 엘지디스플레이 주식회사 | Modulation method of data supply time and driving method and device of liquid crystal display device using the same |
SE0400235D0 (en) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
SE0401578D0 (en) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
US7838522B2 (en) | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
JP5021488B2 (en) | 2004-12-21 | 2012-09-05 | メルク セローノ ソシエテ アノニム | Sulfonylamino cyclic derivatives and uses thereof |
DK1844032T3 (en) | 2005-01-31 | 2011-10-24 | Merck Serono Sa | N-hydroxyamide derivatives and their use |
BRPI0613042A2 (en) | 2005-07-15 | 2010-12-14 | Serono Lab | jnk inhibitors for the treatment of endometriosis |
KR20080044836A (en) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | Jnk inhibitors for the treatment of endometriosis |
CA2616479A1 (en) | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
KR101440982B1 (en) | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | Crystals of laquinimod sodium, and process for the manufacture thereof |
ES2377149T3 (en) | 2006-06-12 | 2012-03-22 | Teva Pharmaceutical Industries Limited | Stable laquinimod preparations |
EP2977049A1 (en) | 2007-12-20 | 2016-01-27 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
CN104311486A (en) | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
PL2458992T3 (en) | 2009-07-30 | 2016-07-29 | Teva Pharma | Treatment of crohn's disease with laquinimod |
SI2467372T1 (en) | 2009-08-10 | 2016-09-30 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
DK2542079T3 (en) * | 2010-03-03 | 2014-08-25 | Teva Pharma | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
CN102781239B (en) * | 2010-03-03 | 2015-01-21 | 泰华制药工业有限公司 | Treatment of lupus arthritis using laquinimod |
KR20160129093A (en) | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | Treatment of lupus nephritis using laquinimod |
WO2011116091A1 (en) | 2010-03-17 | 2011-09-22 | Novartis Ag | Dispenser |
JP2013535437A (en) | 2010-07-09 | 2013-09-12 | テバ ファーマシューティカル インダストリーズ リミティド | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts thereof and uses |
JP5881691B2 (en) | 2010-07-09 | 2016-03-09 | アクティブ バイオテック エイビー | Process for producing quinoline-3-carboxamide |
EA201390074A1 (en) * | 2010-07-09 | 2013-06-28 | Тева Фармасьютикал Индастриз Лтд. | 5-HLOR-4-HYDROXY-1-METHIL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLIN-3-CARBOXAMID, ITS SALT AND APPLICATIONS |
EP2444086A1 (en) | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Combinations comprising DHODH inhibitors and COX inhibitors |
WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
BR112014018485A8 (en) | 2012-02-03 | 2017-07-11 | Teva Pharma | USE OF LAQUINIMOD TO TREAT PATIENTS WITH CROHN'S DISEASE WHO HAVE FAILED FIRST LINE ANTI-TNF THERAPY |
MX2014009889A (en) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-qui noline carboxamide, preparation and uses thereof. |
TW201350467A (en) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide |
TW201400117A (en) | 2012-06-05 | 2014-01-01 | Teva Pharma | Treatment of ocular inflammatory disease using laquinimod |
TW201410244A (en) | 2012-08-13 | 2014-03-16 | Teva Pharma | Laquinimod for treatment of GABA mediated disorders |
AU2013341506A1 (en) | 2012-11-07 | 2015-06-04 | Teva Pharmaceutical Industries Ltd. | Amine salts of Laquinimod |
RU2545056C2 (en) * | 2012-12-10 | 2015-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) | Anti-inflammatory and analgesic agent of 1,2-dihydro-1h-2-oxocinchoninic acid isopropylamide |
MX2015010296A (en) * | 2013-02-15 | 2016-05-05 | Teva Pharma | Treatment of multiple sclerosis with laquinimod. |
SG11201506409RA (en) | 2013-03-14 | 2015-09-29 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
CN106573014A (en) | 2014-04-29 | 2017-04-19 | 梯瓦制药工业有限公司 | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
CN107108510B (en) | 2014-09-23 | 2020-10-23 | 活跃生物技术有限公司 | Quinoline carboxamides for the treatment of multiple myeloma |
EP3180005B1 (en) | 2014-11-19 | 2017-12-27 | Active Biotech AB | Quinoline carboxamides for use in the treatment of leukemia |
BR112022009192A2 (en) | 2019-12-19 | 2022-07-26 | Active Biotech Ab | COMPOSITION, METHOD TO TREAT AN EYE DISEASE OR EYE DISORDER, AND, USE OF A COMPOUND |
CN115209881A (en) | 2020-03-03 | 2022-10-18 | 活跃生物技术有限公司 | Taquinimod, or a pharmaceutically acceptable salt thereof, for use in combination therapy |
IL300068A (en) | 2020-07-23 | 2023-03-01 | Univ Erasmus Med Ct Rotterdam | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
JP2024503372A (en) | 2021-01-18 | 2024-01-25 | アクティブ バイオテック エイビー | tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndromes |
IL308542A (en) | 2021-05-25 | 2024-01-01 | Active Biotech Ab | A plurality of tasquinimod particles and use thereof |
WO2023275248A1 (en) | 2021-07-02 | 2023-01-05 | Active Biotech Ab | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-04-27 SE SE9801474A patent/SE9801474D0/en unknown
-
1999
- 1999-04-26 NZ NZ506641A patent/NZ506641A/en not_active IP Right Cessation
- 1999-04-26 PT PT99947036T patent/PT1073639E/en unknown
- 1999-04-26 HU HU0102084A patent/HU227709B1/en not_active IP Right Cessation
- 1999-04-26 IL IL13816099A patent/IL138160A0/en active IP Right Grant
- 1999-04-26 RS YUP-612/00A patent/RS50029B/en unknown
- 1999-04-26 DK DK99947036T patent/DK1073639T3/en active
- 1999-04-26 JP JP2000545838A patent/JP4045069B2/en not_active Expired - Lifetime
- 1999-04-26 ID IDW20002183A patent/ID26277A/en unknown
- 1999-04-26 AP APAP/P/2000/001933A patent/AP1293A/en active
- 1999-04-26 TR TR2000/03061T patent/TR200003061T2/en unknown
- 1999-04-26 ES ES99947036T patent/ES2188242T3/en not_active Expired - Lifetime
- 1999-04-26 KR KR1020007011944A patent/KR100571534B1/en not_active IP Right Cessation
- 1999-04-26 EE EEP200000613A patent/EE04275B1/en unknown
- 1999-04-26 CN CN99805581A patent/CN1113057C/en not_active Expired - Fee Related
- 1999-04-26 CZ CZ20003849A patent/CZ297439B6/en not_active IP Right Cessation
- 1999-04-26 EP EP99947036A patent/EP1073639B1/en not_active Expired - Lifetime
- 1999-04-26 UA UA2000085078A patent/UA60354C2/en unknown
- 1999-04-26 DE DE69904162T patent/DE69904162T2/en not_active Expired - Lifetime
- 1999-04-26 PL PL99343420A patent/PL190441B1/en unknown
- 1999-04-26 OA OA1200000301A patent/OA11547A/en unknown
- 1999-04-26 WO PCT/SE1999/000676 patent/WO1999055678A1/en active IP Right Grant
- 1999-04-26 RU RU2000129672/04A patent/RU2197481C2/en not_active IP Right Cessation
- 1999-04-26 BR BRPI9909925-0A patent/BR9909925B1/en not_active IP Right Cessation
- 1999-04-26 ME MEP-2000-612A patent/ME00870B/en unknown
- 1999-04-26 AU AU43013/99A patent/AU747550B2/en not_active Ceased
- 1999-04-26 AT AT99947036T patent/ATE228505T1/en active
- 1999-04-26 CA CA002329788A patent/CA2329788C/en not_active Expired - Fee Related
-
2000
- 2000-08-30 IL IL138160A patent/IL138160A/en not_active IP Right Cessation
- 2000-08-31 IS IS5615A patent/IS2082B/en unknown
- 2000-09-01 ZA ZA200004601A patent/ZA200004601B/en unknown
- 2000-10-19 NO NO20005254A patent/NO315606B1/en not_active IP Right Cessation
- 2000-10-26 HR HR20000726A patent/HRP20000726B1/en not_active IP Right Cessation
-
2001
- 2001-08-07 HK HK01105489A patent/HK1036618A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000129672A (en) | Quinoline derivatives | |
RU2213733C2 (en) | Derivatives of quinoline, method for their preparing (variants), pharmaceutical composition and method of treatment with their using | |
RU2001104342A (en) | Quinoline derivatives | |
RU2001104344A (en) | Quinoline derivatives | |
RU2145595C1 (en) | Nitroxycompounds and pharmaceutical composition based on thereof showing anti-inflammatory, analgetic and antithrombocytic activity | |
FI77847C (en) | Process for the preparation of therapeutically useful alkoxy acid derivatives. | |
EP0283970A3 (en) | New peptide compounds, a process for the preparation thereof and pharmaceutical composition comprising the same | |
RU99115766A (en) | BENZOTIOPHENCARBOXAMIDE DERIVATIVES CONTAINING THEIR PGD2 ANTAGONISTS PHARMACEUTICAL COMPOSITION AND MEDICINE | |
CA2407972A1 (en) | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | |
KR950003294A (en) | Tricyclic benzazine vazopressin antagonist | |
RU2002103867A (en) | Aminobenzophenones as inhibitors of IL-1 β and TNF-α | |
JP5061134B2 (en) | Kappa opioid receptor agonist comprising 2-phenylbenzothiazoline derivative or a salt thereof | |
SE8800638L (en) | ANTIHYPERCHOLESTEROLEMIC TETRAZOLE COMPOUNDS | |
WO2009007536A2 (en) | Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics | |
CA2126118A1 (en) | 5-Amino-8-Methyl-7-Pyrrolidinylquinoline-3-Carboxylic Acid Derivative | |
RU96123227A (en) | AMIDIC DERIVATIVES AND THEIR THERAPEUTIC USE | |
US4067996A (en) | Phenylacetic acid derivatives | |
CZ280084B6 (en) | Derivatives of 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanes, process for their preparation and pharmaceutical preparation in which said derivatives are comprised | |
US4176194A (en) | Oxyalkanoic acid derivatives | |
US3836656A (en) | Substituted purines as hypolipidemics | |
BRPI0211025B1 (en) | a new compound for the treatment of impotence | |
JP3145803B2 (en) | 3-cycloalkyl-2-propenamide derivative | |
AU611736B2 (en) | (4-hydroxy-5,6-bis(alkoxycarbonyl or lactone)-7- dialkoxyphenyl)benzo(b)thiophene, quinoline and carbazole derivatives useful as hypolipidemic agents | |
FI883484A (en) | BENZIMIDAZOLDERIVAT, DERAS FRAMSTAELLNING OCH ANVAENDNING VID TERAPI. | |
EP0593697B1 (en) | Mercapto-acetamide derivatives |